respiratory distress syndrome, asthma, emphysema, delayed type hypersensitivity reaction, systemic lupus erythmatosus, thermal injury, autoimmune thyroiditis, experimental allergic encephalomyelitis, multiple sclerosis, diabetes, Reynaud's syndrome, neutrophilic dermatosis, inflammatory bowel disease, Grave's disease, glomerulonephritis, gingivitis, periodontitis, hemolytic uremic syndrome, ulcerative colitis, Crohn's decease, necrotizing enterocoltis, granulocyte transfusion associated syndrome, and cytokine-induced toxicity.

A12 Cont

99. (New) A method of treating a condition characterized by P- or E-selectin mediated intercellular adhesion comprising administering a therapeutically effective amount of a composition of any one of claims 29, 39, 49, 59, 69, 79, or 89 to a mammalian subject.

REMARKS

Claims 1-95 are pending in the instant application. Claims 22-26, 32-36, 42-46, 52-56, 62-66, 72-76, 82-86, and 90-95 have been canceled. Claims 8, 13, 27, 37, 47, 57, 67, 77, and 87 have been amended and new claims 96, 97, 98, and 99 have been added. Accordingly, claims 1-21, 27-31, 37-41, 47-51, 57-61, 67-71, 77-81, and 87-89, and 96-99 are currently pending. For the Examiner's convenience, the pending claims are set forth in Appendix A.

Support for the amendments to claims 8, 13, 27, 37, 47, 57, 67, 77, and 87 and new claims 96, 97, 98, and 99 may be found in the specification and claims as originally filed. In particular, support for new claims 96-99 may be found in the specification at page 18, line 23 through page 19, line 14. Applicants submit herewith a **"Version with Markings to Show Changes Made,"** which indicates the specific amendments made to the specification and the claims. *No new matter has been added.*

Any amendments to and/or cancellation of the claims should in no way be construed as an acquiescence to any of the Examiner's rejections and was done solely to expedite prosecution. Applicants reserve the right to pursue the claims as originally filed in this or a separate application(s).

CONCLUSION

It is respectfully submitted that this application is in condition for allowance. If a telephone conversation with Applicants' attorney would help expedite the prosecution of the above-identified application, the Examiner is urged to call Applicants' attorney at (617) 227-7400.

Respectfully submitted,

Amy E. Mandragouras, Esq.
Registration No. 36,207
Attorney for Applicants

LAHIVE & COCKFIELD, LLP
28 State Street
Boston, MA 02109
Tel. (617) 227-7400

Dated: November 27, 2001

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the specification

The first paragraph on page 1 has been replaced with the following re-written paragraph:

This application is a continuation of application Serial No. 09/026,001, filed February 18, 1998, pending, which is a continuation-in-part of application Serial No. 09/012,637, filed January 23, 1998, now abandoned, which was a continuation-in-part of application Serial No. 08/843,373, filed April 15, 1997, now abandoned.

The paragraph beginning at page 30, line 15 has been amended as follows:

Following SDS-PAGE and autoradiography, a novel ~50kD band appeared in the ~~smple~~ sample lane where 50 nanograms of purified bovine enterokinase had been inclubated with the conditioned medium (see Fig. 3). This band is consistent with the expected molecular weight of the mature protease when the propeptide (~23 kD) is cleaved off.

In the Claims:

Claims 22-26, 32-36, 42-46, 52-56, 62-66, 72-76, 82-86, and 90-95 have been cancelled.

Claims 8, 13, 27, 37, 47, 57, 67, 77, and 87 have been amended as follows:

8. A method of treating an inflammatory disease ~~which comprises~~ comprising administering a therapeutically effective amount of a composition of claim 7 to a mammalian subject.

13. A method of treating an inflammatory disease ~~which comprises~~ comprising administering a therapeutically effective amount of a composition of claim 12 to a mammalian subject.

27. A protein produced according to ~~the process of claim 26~~ a process comprising:

(a) in a suitable culture medium, growing a culture a host cell transformed with an isolated polynucleotide comprising the nucleotide sequence of SEQ ID NO:5 operably linked to an expression control sequence; and

(b) purifying the protein from the culture.

37. A protein produced according to ~~the process of claim 26~~ a process comprising:

(a) in a suitable culture medium, growing a culture a host cell transformed with an isolated polynucleotide comprising the nucleotide sequence of SEQ ID NO:7 operably linked to an expression control sequence; and

(b) purifying the protein from the culture.

47. A protein produced according to ~~the process of claim 26~~ a process comprising:

(a) in a suitable culture medium, growing a culture a host cell transformed with an isolated polynucleotide comprising the nucleotide sequence of SEQ ID NO:9 operably linked to an expression control sequence; and

(b) purifying the protein from the culture.

57. A protein produced according to ~~the process of claim 26~~ a process comprising:

(a) in a suitable culture medium, growing a culture a host cell transformed with an isolated polynucleotide comprising the nucleotide sequence of SEQ ID NO:11 operably linked to an expression control sequence; and

(b) purifying the protein from the culture.

67. A protein produced according to ~~the process of claim 26~~ a process comprising:

(a) in a suitable culture medium, growing a culture a host cell transformed with an isolated polynucleotide comprising the nucleotide sequence of SEQ ID NO:13 operably linked to an expression control sequence; and

(b) purifying the protein from the culture.

77. A protein produced according to ~~the process of claim 26~~ a process comprising:

(a) in a suitable culture medium, growing a culture a host cell transformed with an isolated polynucleotide comprising the nucleotide sequence of SEQ ID NO:15 operably linked to an expression control sequence; and

(b) purifying the protein from the culture.

87. A protein produced according to ~~the process of claim 26~~ a process comprising:

(a) in a suitable culture medium, growing a culture a host cell transformed with an isolated polynucleotide comprising the nucleotide sequence of SEQ ID NO:17 operably linked to an expression control sequence; and

(b) purifying the protein from the culture.

New claims 96, 97, 98, and 99, have been added as follows:

96. (New) A method of treating a condition characterized by P- or E-selectin mediated intercellular adhesion comprising administering a therapeutically effective amount of a composition of claim 7 to a mammalian subject.

97. (New) A method of treating a condition characterized by P- or E-selectin mediated intercellular adhesion comprising administering a therapeutically effective amount of a composition of claim 12 to a mammalian subject.

98. (New) The method of claims 96 or 97 wherein said condition characterized by P- or E-selectin mediated intercellular adhesion is selected from the group consisting of: myocardial infarction, vessel restenosis, thrombosis, bacterial or viral infection, metastatic conditions, inflammatory disorders such as arthritis, acute respiratory distress syndrome, asthma, emphysema, delayed type hypersensitivity reaction, systemic lupus erythmatosus, thermal injury, autoimmune thyroiditis, experimental allergic encephalomyelitis, multiple sclerosis, diabetes, Reynaud's syndrome, neutrophilic dermatosis, inflammatory bowel disease, Grave's disease, glomerulonephritis, gingivitis, periodontitis, hemolytic uremic syndrome, ulcerative colitis, Crohn's decease, necrotizing enterocoltis, granulocyte transfusion associated syndrome, and cytokine-induced toxicity.

99. (New) A method of treating a condition characterized by P- or E-selectin mediated intercellular adhesion comprising administering a therapeutically effective amount of a composition of any one of claims 29, 39, 49, 59, 69, 79, or 89 to a mammalian subject.